Skip to Content

NovoSeven now available in 2.4 mg vial

PRINCETON, N.J. -- Novo Nordisk Pharmaceuticals announced that NovoSeven Coagulation Factor VIIa (Recombinant) is now available in a 2.4 mg vial size in the United States. NovoSeven is indicated for the treatment of bleeding episodes in hemophilia A or B patients with inhibitors (antibodies) to coagulation Factors VIII or IX.

Robert Caspari, M.D., vice president of BioPharmaceuticals, Novo Nordisk, said, "The availability of new 2.4 mg vial will give health care professionals the option to select the most convenient vial size when treating their patients."

He added: "NovoSeven is the only recombinant Factor VIIa available for effective, prompt and reliable treatment of bleeding episodes in individuals with antibodies to Factor VIII or IX. NovoSeven eliminates the risk of human viral contamination, such as HIV or hepatitis because no human albumin or other human-derived proteins are used in manufacturing."

NovoSeven's  direct action at the site of injury minimizes risk of systemic coagulation and provides proven efficacy of 91 percent, depending on the type and severity of the bleed. The producte is now available in 1.2 mg, 2.4 mg, and 4.8 mg vials.

For further information, visit

Source: Novo Nordisk Pharmaceuticals, Inc.

Posted: June 2002